Explore All 789 Divestiture Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | September 9, 2020 |
| Target | Noden Pharma DAC |
| Sector | Life Science |
| Buyer(s) | Stanley Capital |
| Sellers(s) | PDL BioPharma |
| Deal Type | Divestiture |
| Deal Value | 53M USD |
FILTER BY
Stanley Capital is a private equity partnership that pursues healthcare and technology investments. The Firm targets businesses valued from $250 million to $2.5 billion with defensible business models and opportunities for growth. Stanley Capital was formed in 2019 and is headquartered in London.
| Deal Context for Buyer | # |
|---|---|
| Overall | 1 of 4 |
| Sector: Life Science | 1 of 2 |
| Type: Divestiture | 1 of 1 |
| Country: Ireland | 1 of 1 |
| Year: 2020 | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-01-01 |
Qinecsa Solutions
London, United Kingdom Qinecsa Solutions is a global provider of pharmacovigilance software and services. Qinecsa Solutions is based in London, United Kingdom. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1986 |
| Sector | Life Science |
| Employees | 109 |
| Revenue | 55M USD (2019) |
PDL BioPharma is a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies. PDL BioPharma was founded in 1986 and is based in Incline Village, Nevada.
| Deal Context for Seller | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science | 1 of 1 |
| Type: Divestiture | 1 of 1 |
| Country: Ireland | 1 of 1 |
| Year: 2020 | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-10-26 |
Neos Therapeutics
Grand Prairie, Texas, United Kingdom Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets including Boxed WARNING), Cotempla XR-ODT™ (methylphenidate) extended-release orally disintegrating tablets including Boxed WARNING), and Adzenys-ER™ (amphetamine) extended-release oral suspension including Boxed WARNING), all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. |
Buy | - |
